Merck's Flexeril
Executive Summary
Firm has requested that an ANDA suitability petition filed by Central Pharmaceuticals for a 15 mg b.i.d. version of cyclobenzaprine be denied on the ground that Merck's data establish the drug's safety and efficacy only in a 10 mg t.i.d. regimen.